États-Unis · Plateformes & données · MarketBeat

What Alpha Cognition (ACOG) Said on Its Q3 Earnings Call

Publié par MarketBeat · États-Unis il y a 1 h

Image from MarketBeat Media, LLC. · MarketBeat

Résumé détaillé

Alpha Cognition (NASDAQ:ACOG) reported third-quarter 2026 net product revenue of approximately $7.8 million, up 30% from the preceding quarter, as prescriptions and prescriber adoption increased for its Alzheimer’s treatment ZUNVEYL. Management reiterated its goal of reaching operating profitabilit

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

What Alpha Cognition (ACOG) Said on Its Q3 Earnings Call

Résumé détaillé

À lire aussi

Dell Technologies vs. Taiwan Semiconductor: Which Technology Stock Is a Better Buy for 2027?

Your holiday credit-card bills are going up. What you can do to ease the pain.

Here are the major earnings before the open Thursday

Prediction markets tied to clinical trials and drug approvals draw lawmakers' ire

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Cogna approves buyback program for up to 141,792,187 common shares

What Alpha Cognition (ACOG) Said on Its Q3 Earnings Call

Résumé détaillé

Partager

À lire aussi

Dell Technologies vs. Taiwan Semiconductor: Which Technology Stock Is a Better Buy for 2027?

Your holiday credit-card bills are going up. What you can do to ease the pain.

Here are the major earnings before the open Thursday

Prediction markets tied to clinical trials and drug approvals draw lawmakers' ire

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

Cogna approves buyback program for up to 141,792,187 common shares